Literature DB >> 7569023

An ICRU 50 radiotherapy treatment chart.

A F Monti1, A Ostinelli, M Frigerio, D Cosentino, A Bossi, L F Cazzaniga, L Scandolaro, M C Valli.   

Abstract

We illustrate a radiotherapy treatment chart elaborated to fulfil the necessity for clarity in reporting information about radiotherapeutic treatment. The schematic configuration of the chart results from the experience and the cooperation of physicists, physicians and technicians, and an effort has been made to satisfy Levels 2/3 of the ICRU 50 recommendations. The chart has been divided into four sections corresponding to different kinds of information: a cover sheet, a section containing data about the treatment planning geometry and the console parameters adopted, a section showing dosimetric data, and a section showing treatment data. The chart seems to give a good level of accuracy in reporting treatment plan information.

Mesh:

Year:  1995        PMID: 7569023     DOI: 10.1016/0167-8140(95)01541-n

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Radiation dose and late failures in prostate cancer.

Authors:  Peter B Morgan; Alexandra L Hanlon; Eric M Horwitz; Mark K Buyyounouski; Robert G Uzzo; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

2.  Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer.

Authors:  Niraj Pahlajani; Karen J Ruth; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Gerald E Hanks; Robert A Price; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-07-15       Impact factor: 7.038

3.  Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Authors:  Pino Alcantara; Alexandra Hanlon; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

4.  Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Navesh K Sharma; Tianyu Li; David Y Chen; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-01       Impact factor: 7.038

5.  How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?

Authors:  David J D'Ambrosio; Karen Ruth; Eric M Horwitz; Robert G Uzzo; Alan Pollack; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

6.  Does treatment duration affect outcome after radiotherapy for prostate cancer?

Authors:  David J D'Ambrosio; Tianyu Li; Eric M Horwitz; David Y T Chen; Alan Pollack; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-09       Impact factor: 7.038

7.  Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy.

Authors:  Peter B Morgan; Alexandra L Hanlon; Eric M Horwitz; Mark K Buyyounouski; Robert G Uzzo; Alan Pollack
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

8.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

9.  Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

Authors:  Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

10.  Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas.

Authors:  Pavlos Vlachogiannis; Olafur Gudjonsson; Anders Montelius; Erik Grusell; Ulf Isacsson; Kristina Nilsson; Erik Blomquist
Journal:  Acta Neurochir (Wien)       Date:  2017-10-24       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.